Načítá se...
Targeting EPO and EPO RECEPTOR PATHWAYS in Anemia and Dysregulated Erythropoiesis
INTRODUCTION: Recombinant human erythropoietin (rhEPO) is a first-line therapeutic for the anemia of chronic kidney disease, cancer chemotherapy, AIDS (Zidovudine therapy) and lower-risk myelodysplastic syndrome. However, rhEPO frequently elevates hypertension, is costly and may affect cancer progre...
Uloženo v:
| Vydáno v: | Expert Opin Ther Targets |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4829957/ https://ncbi.nlm.nih.gov/pubmed/26419263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14728222.2016.1090975 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|